blocker, in patients with anovulation and cycle abnormalities. Endogenous opioids are among the factors involved in the 3 To whom correspondence should be addressed inhibition of the hypothalamic pulse generator that directs Patients suffering from normogonadotrophic anovulation gonadotrophin releasing hormone (GnRH) secretion. Naland infertility are initially treated with clomiphene citrate.
inhibition of the hypothalamic pulse generator that directs Patients suffering from normogonadotrophic anovulation gonadotrophin releasing hormone (GnRH) secretion. Naland infertility are initially treated with clomiphene citrate.
trexone establishes chronic blockade of the hypothalamic Those who do not respond to clomiphene citrate usually opioid receptors. Wildt et al. (1993a,b) reported that naltrexone receive gonadotrophin treatment which is labour-intensive, treatment can restore ovulation and normal menstrual cycles expensive, and associated with an increased risk of multiple in patients with various grades of hypothalamic ovarian failure. pregnancies and ovarian hyperstimulation syndrome. We
In contrast, Armeanu et al. (1992) and Couzinet et al. (1995) 
treated 22 patients with clomiphene resistant normogona-
could not demonstrate an increase in gonadotrophin secretion dotrophic anovulation with naltrexone (an opioid receptor or resumption of ovulation in women with hypogonadotrophic blocker) alone or naltrexone in combination with an antihypogonadism after naltrexone treatment. In a group of patients oestrogen. In 19 patients ovulation and resumption of a with weight-loss-related amenorrhoea, administration of nalregular menstrual cycle was achieved and in 12 out of trexone resulted in the restoration of a normal menstrual cycle 19 a singleton pregnancy was observed. In conclusion, (Genazzani et al., 1993) . In women with polycystic ovarian ovulation can be induced successfully using naltrexone syndrome LH concentrations were normalized after naltrexone alone or naltrexone in combination with an anti-oestrogen treatment (Lanzone et al., 1993; Cagnacci et al., 1994) . in clomiphene citrate resistant anovulatory patients. ComWe wished to investigate whether patients with subfertility pared to gonadotrophin induction of ovulation, this method due to normogonadotrophic anovulation, who were clomiphene is safe, simple and inexpensive. The Netherlands) in doses up to 150 mg for 5 days with no signs of anovulatory patients will prove to be clomiphene citrate ovulation on ultrasound, nor resumption of a regular cycle.
Introduction

Materials and methods
resistant (Franks et al., 1985) .
Administration of human menopausal gonadotrophins probe (Toshiba Medical Systems, Europe BV, Zoetermeer, The Netherlands) from cycle day 9 onwards. When a leading follicle (Ͼ10 mm diameter) was detected, ultrasonographic monitoring was performed every other day until ovulation had occurred. Progesterone concentrations were determined 1 week later. Progesterone was estimated in a commercially available heterogeneous competitive magnetic separation immunoassay (Bayer, Tarrytown, NY, USA). The total variation coefficient is between 2.8 and 13.8%). Figure 1 . Number of menstrual periods in 22 anovulatory women If the patient did not respond to naltrexone alone, 100 mg of before and after treatment with naltrexone. Boxes indicate the 25th clomiphene citrate for 5 days was added to the continuous naltrexone and 75th percentile, with a solid line within the box showing the therapy. If ovulation was demonstrated, the present treatment was median value, whereas whiskers show the largest and smallest continued using basal body temperature chart (BBT) instead of observed value that is not an outlier. Outliers are shown by asterisks in the plot and are defined as values more than three boxultrasound detection of ovulation. Up to six cycles per patient were lengths from the 25th or 75th percentile. Data shown for women included in this study. Ovulation was considered to have taken place before naltrexone treatment include several amenorrhoeic patients, in the case of ultrasonographic signs of ovulation, and/or elevated thus resulting in a menstrual frequency skewed towards zero, and midluteal progesterone (Ͼ30 nmol/l), and/or biphasic BBT, and/or the coincidence of the 25th percentile and lowest observed value. resumption of a regular menstrual cycle and if pregnancy occurred. Naltrexone was discontinued in the case of a positive pregnancy test or when patients had no follicular growth after 21 days of combined frequency of menstrual periods per year changed from 0.5 naltrexone and clomiphene citrate treatment.
(range 0-6) to 11.5 (range 0-13.5) after treatment. Three patients did not respond to combined therapy. Prior to treatment Hormone assays two of those patients had amenorrhoea and one patient was Baseline hormone samples were drawn at day 1, 2, 3 or 4 of a spontaneous or progestagen-induced menstrual bleeding. All horseverely oligomenorrhoeic (two periods/year). All three had mones were assayed by commercially available kits. Plasma LH and polycystic ovarian disease (PCOD).
FSH concentrations were determined in a heterogeneous sandwich
Only minor side-effects were observed during drug adminismagnetic separation assay (Bayer, Tarrytown, NY, USA). For LH the tration. Some patients reported some discomfort (dizziness, inter-and intra-assay coefficient of variation was 4.5% and for FSH anxiety, restlessness or malaise) during the first few days of 3.2%. Oestradiol was determined using a commercially available naltrexone treatment. These symptoms usually disappeared radioimmunoassay (DPC, Los Angeles, CA, USA) with intra-and spontaneously after several days.
inter-assay coefficients of variation between 4.2 and 7.4%. Oestradiol concentrations Ͻ200 pmol/l were measured using a double antibody radioimmunoassay with a total variation coefficient 2.7%. Testosterone Discussion was assayed using coat-a-count radioimmunoassay (DPC) whose total This is the first study which shows the successful induction Table I . In 19 of 22 patients ovulation was achieved. Four patients ment with clomiphene citrate are considered to be the most difficult group of patients to treat. Most have PCOD, and ovulated on naltrexone alone, 18 patients needed clomiphene citrate. Twelve patients conceived during treatment. Three when they are treated with HMG their ovaries tend to hyperrespond. In order to avoid this complication, frequent monpatients conceived in their first cycle, four in their second, two in their third, two in their fourth cycle and one in her fifth itoring is essential during HMG therapy, which is very timeconsuming for both doctor and patient. cycle. All pregnancies were singleton pregnancies. At the time of going to press, two spontaneous abortions have occurred
We found that 86% of our normogonadotrophic clomiphene citrate resistant patients responded to naltrexone or naltrexone and 10 pregnancies are ongoing. Figure 1 shows the change in frequency of menstrual and clomiphene citrate. Ovarian hyperstimulation syndrome and multiple pregnancies were avoided; in our study only periods following naltrexone treatment. In those patients who conceived, the virtual cycle length of that cycle was estimated monofollicular growth was observed and all pregnancies were singleton pregnancies. The oral administration of the drug is by extrapolating from the length of the follicular phase. Median simple. Our results suggest that, once ovulatory response is Obstet. Gyneacol., 62, [196] [197] [198] [199] [200] [201] [202] obtained, monitoring can be limited, thus making frequent Lanzone, A., Apa, R., Fulgesu, A.M. et al. (1993) Long-term naltrexone visits unnecessary. The resumption of regular cycles proved treatment normalizes the pituitary response to gonadotrophin-releasing hormone in polycystic ovarian syndrome. Fertil. Steril., 59, [734] [735] [736] [737] to be consistent: the seven patients who ovulated but did not Navot, D., Bergh, P.A. and Laufer, N. (1992) There will never be a single solution to the cause of University Press, Cambridge. normogonadotrophic anovulation. All along the hypothalamicWildt, L., Leyendecker, G., Sir-Petermann, T. and Waibel-Treber, S. (1993a) pituitary-ovarian axis, factors may be responsible for cycle Treatment with naltrexone in hypothalamic ovarian failure: induction of ovulation and pregnancy. Hum. Reprod., 8, [350] [351] [352] [353] [354] [355] [356] [357] [358] abnormalities. Clomiphene citrate is thought to displace endoWildt, L., Sir-Petermann, T., Leyendecker, G. et al. (1993b) an increased FSH production in the pituitary. Opioid antagonists may affect follicle development and ovulation by modulating the GnRH secretion and thus influencing major endocrine regulatory pathways. Apparently, some anovulatory, clomiphene resistant patients may respond favourably to inhibition of their endogenous opioids. This suggests that in these cases an opioid-dependent hypothalamic-pituitary dysfunction, possibly similar to the functional defect in hypogonadotrophic hypogonadism, is responsible for the abnormal cycle dynamics. In addition, patients who do not respond to either clomiphene or naltrexone alone may start ovulating during combination therapy. It seems that the mechanism of follicular selection and dominance remains operative or is restored, since only monofollicular development and singleton pregnancies were obtained. Naltrexone offers an effective, safe, simple and cheap alternative to gonadotrophin ovulation induction in clomiphene resistant patients with cycle disturbances.
